Introduction: Nowadays, radioisotopes have a lot of therapeutic and diagnostic applications in nuclear medicine. The technetium-99m radioisotope is widely used in the diagnostic field. The technetium-99m radioisotope is widely used in the diagnostic field. In this study, in order to increase the absorption dose in thyroid cancer cells, the radioactive drug technetium-99m which ...

Introduction: The determination of patient’s absorbed dose is the first step of radiation protection which depends on the quantification of organ activity in nuclear medicine. The aim of the present study was to determine the absorbed dose by patient’s uterus following myocardial perfusion scan with 99mTC-sestamibi using Theroluminescnce dosimetry (TLD) and conjugate-view metho...

Introduction: The goal of any type of radiation therapy in the treatment of tumors, in addition to destroying cancer cells, is to minimizing radiation to nearby healthy cells and thus reducing side damages. For this purpose, targeted radiation therapy (TRT) is more effective in treating of single cells or small cluster of cells. The main factor in the success of this method is...

Introduction: Thyroid cancer is at the ninth from ten of common malignant cancer. A man has higher risk to get Thyroid cancer that a woman has. This organ is lain near human neck. The use of radioactive I-131, I-123 and Tc-99m for diagnosis of thyroid cancer has a risk where other organs around Thyroid will accept dose of radiation. One of the risks is large dose which is accep...

UNLABELLED Dosimetric calculations are performed with an increasing frequency before or after treatment in targeted radionuclide therapy, as well as for radiation protection purposes in diagnostic nuclear medicine. According to the MIRD committee formalism, the mean absorbed dose to a target is given by the product of the cumulated activity and a dose-conversion factor, known as the S factor. S...

objective(s):lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “no carrier added” (nca) 177lu. we have radiolabelled dota-conjugated peptide dota‐(tyr3)‐octreotate with nca 177lu (“nca-lutate”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. in this paper, we report on...

UNLABELLED Active bone marrow is one of the more radiosensitive tissues in the human body and, hence, it is important to predict and possibly avoid myelotoxicity in radionuclide therapies. The MIRD schema currently used to calculate marrow dose generally requires knowledge of the patient's total skeletal active marrow mass -- a value that, at present, cannot be directly measured. Conceptually, ...

UNLABELLED We assessed the efficiency and toxicity of brief intraperitoneal radioimmunotherapy using high activities of (125)I-labeled monoclonal antibody (mAb) in the treatment of small-volume peritoneal carcinomatosis. METHODS Brief intraperitoneal radioimmunotherapy consisted of a 185-MBq (740 MBq/mg) intraperitoneal injection of (125)I-35A7 (an anti-carcinoembryonic antigen mAb) into athy...